Home › Compare › EMOR vs MRK

EMOR vs MRK: Dividend Comparison 2026

EMOR yields 5000.00% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMOR wins by $62217131802825.30M in total portfolio value
10 years
EMOR
EMOR
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full EMOR calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — EMOR vs MRK

📍 EMOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMORMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMOR + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EMOR pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMOR
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, EMOR beats the other by $50,882,683,244,271,470,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMOR + MRK for your $10,000?

EMOR: 50%MRK: 50%
100% MRK50/50100% EMOR
Portfolio after 10yr
$31108565901412.70M
Annual income
$29,930,990,143,689,110,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EMOR
No analyst data
Altman Z
-337.8
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMOR buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMORMRK
Forward yield5000.00% ✓2.81%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$62217131802825.35M ✓$57.7K
Annual income after 10y$59,861,980,287,378,210,000.00 ✓$10,113.78
Total dividends collected$62057786341622.61M ✓$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EMOR vs MRK ($10,000, DRIP)

YearEMOR PortfolioEMOR Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$510,700$500,000.00$11,213$373.04+$499.5K → EMOR
2$24,410,935$23,864,485.98$12,667$512.06+$24.40M → EMOR
3$1,092,192,501$1,066,072,800.30$14,439$708.14+$1092.18M → EMOR
4$45,746,366,951$44,577,720,975.17$16,640$988.16+$45746.35M → EMOR
5$1,793,932,828,410$1,744,984,215,772.56$19,432$1,394.07+$1793932.81M → EMOR
6$65,871,973,805,320$63,952,465,678,921.49$23,057$1,992.90+$65871973.78M → EMOR
7$2,265,146,887,602,700$2,194,663,875,631,007.20$27,889$2,894.79+$2265146887.57M → EMOR
8$72,954,689,148,998,180$70,530,981,979,263,280.00$34,518$4,286.29+$72954689148.96M → EMOR
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$43,912$6,494.35+$2201076182660.84M → EMOR
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$57,714$10,113.78+$62217131802825.30M → EMOR

EMOR vs MRK: Complete Analysis 2026

EMOR — Stock

Healixa Inc. operates as a technology company with assets in both healthtech and fintech. It offers tech solutions to enterprise partner channels across a range of industries, including employer benefits, travel, pharma, logistics, and other. Healixa Inc. also operates digital pharmacy marketplace. The company was formerly known as Emerald Organic Products Inc. and changed its name to Healixa Inc. in April 2021. The company was founded in 1977 and is based in Holbrook, New York.

Full EMOR Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EMOR vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMOR vs SCHDEMOR vs JEPIEMOR vs OEMOR vs KOEMOR vs MAINEMOR vs JNJEMOR vs ABBVEMOR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.